Real-world comparison of the effectiveness between ustekinumab and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.

Fiche publication

mai 2024

Journal of Crohn's & colitis

Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine

Tous les auteurs :
Fumery M, Serrero M, Bouguen G, Amiot A, Altwegg R, Nachury M, Vuitton L, Treton X, Caillo L, Pereira B, Buisson A

Both vedolizumab and ustekinumab can be considered for the treatment of ulcerative colitis (UC) but head-to-head trials are lacking.

J Crohns Colitis. 2024 05 14;: